 |
|
| ATHEROSCLEROSIS XI
| |
| | |
|
|
 Proceedings of the XIth International Symposium on Atherosclerosis, Paris, 5 - 9 October 1997
Edited by
B. Jacotot, Service de Médecine V, Hôpital Henri Mondor, Créteil, France
D. Mathé, Institut de Protection et de Sûreté Nucléaire, Fontenay aux Roses Cedex, France
J.-C. Fruchart, Département d'Athérosclérose, INSERM, Institut Pasteur, Lille Cedex, France
Included in series
International Congress, 1155
Description
International Congress Series 1155
These Proceedings will allow the wide dissemination of the present situation in the research on athero-thrombosis.
The volume contains review presentations and new advances on all fields related to cardiovascular diseases: lipoprotein metabolism, genetic,
epidemiology, vascular biology, thrombosis,
hypertension, diabetes, obesity, nutrition, pharmacology, clinical trials, therapy and risk
factors.
Audience
Research Scientist and Physicians in the following fields:
Cardiology, Epidemiology, Internal Medicine, Nutrition, Obesity, Diabetes, Vascular Biology, Genetics, Haemostasis and Hypertension.
Contents
Preface. Plenary Lectures.
Genetics.
The apoE-deficient mouse model of atherosclerosis
(J.L. Breslow).
Increasing the
throughput of mouse studies to search DNA sequence
for function (E.M. Rubin, D.J. Smith).
Use of transgenic animal models to study enzymes
involved in
lipoprotein metabolism and atherosclerosis (S.Santamarina-Fojo, J.M. Hoeg, H.B. Brewer, Jr.). Genetic dissection of high-density
lipoprotein metabolism and
reverse cholesterol transport (G. Assmann et al.).
Leptin, leptin receptors and the regulation of
body weight
(J.M. Friedman).
PPAR activators improve glucose homeostasis by changing fatty
acid partitioning
(G. Martin et al.).
Epidemiology, nutrition, pharmacology
.
The WHO MONICA project: changes in coronary risk in the 1980s
(A. Evans et al.).
Recent progress in the epidemiology of haemostatic factors
(G.D.O. Lowe).
The pleiotropic effects of drugs affecting lipid metabolism
(J. Davignon).
Arterial wall atherogenesis
.
Interaction of oxidized LDL with arterial proteoglycans
(A. Chait et al.).
The increasing significance of the unstable atheroma
(R.T. Lee, P. Libby).
Probing the etiology of elevated plasma levels of Lp(a) in
African-Americans (V. Mooser, J. Cohen, H.H. Hobbs).
Advanced glycoxidation: a vascular enemy with many faces
(H. Vlassara).
Lipoprotein
metabolism.
Receptor-dependent interaction of native and modified lipoproteins
with liver: a concerted action of various cell types
(T.J.C. van Berkel et al.).
Expanding roles for apolipoprotein E in health and disease
(R.W. Mahley).
Antiatherogenic effects
of high-density lipoproteins: mechanisms
(P.J. Barter et al.).
Cholesteryl ester transfer protein deficiency: virtue or vice?
(Y. Matsuzawa et al.).
Postprandial lipaemia and coronary heart disease
(A. Hamsten et al.).
History of International
Atherosclerosis Society a personal journey
(M.D. Haust).
Educational Lectures.
Naked cDNA encoding secreted proteins for intra-arterial
and
intramuscular gene transfer
(T. Asahara et al.).
Fish oils, lipids and coronary artery disease
(P.J. Nestel).
New insights
into the mechanisms of atherosclerosis
(R. Ross).
A preventive and therapeutic approach in atherosclerosis
(W.W. Parmley).
Primary
prevention program in North Karelia: predicting mortality
from changes in CHD risk factors
(M.J. Tikkanen, E. Vartiainen).
State-of-the-Art
Symposia.
The concept of the vulnerable plaque in coronary heart disease
(M.J. Davies).
The Long-Term Intervention with Pravastatin
in Ischaemic Disease
(LIPID) Study
(A.M. Tonkin, P.P. Glaziou on behalf of the LIPID Study Group).
New insights in diabetes and coronary
artery disease
(R.W. Nesto).
Molecular mechanisms of action in fenofibrate
(B. Staels, J. Auwerx, J.-C. Fruchart).
Insulin resistance,
compensatory hyperinsulinemia and dyslipidemia in syndrome X
(G.M. Reaven).
The Diabetes Atherosclerosis Intervention Study (DAIS)
(The DAIS Project Group, prepared by G. Steiner).
Results of the Lipoprotein and Coronary Atherosclerosis Study (LCAS)
(C.M. Ballantyne et al.).
Statins and coronary artery disease; it's the clinical endpoints that count
(G. Jackson).
Optimal reduction in cardiovascular
risk: who should we treat with
HMG-CoA reductase inhibitors?
(J.J.P. Kastelein).
Workshops.
Extracellular matrix of the
vessel and cell matrix interactions during
atherogenesis.
Collagens and atherosclerosis: cell-collagen interaction
(M.J. Barnes,
C.G. Knight, R.W. Farndale).
Proteoglycan lipoprotein interactions
(M. Bihari-Varga).
The elastin-laminin receptor in atherogenesis
(M.P. Jacob).
Elastase and elastase inhibitors and pulmonary and coronary artery disease
(M. Rabinovitch).
Physicochemical interaction
between plasma lipoproteins and the endothelial cell membrane and vascular matrix proteoglycans
(G. Siegel et al.).
Restenosis
and remodeling.
Remodeling rather than neointima formation explains restenosis:
insights from experimental studies in pigs
(H.R.
Andersen).
Platelets and arterial remodeling
(L. Badimon, J.J. Badimon).
Arterial smooth muscle cell phenotypic modulation after
angioplasty
(.H. Louis).
Role of specific smooth muscle cell populations in atherosclerosis
and restenosis
(P. Pauletto et al.).
Proliferation
and death in monoclonal atherosclerotic lesions
(S.M. Schwartz et al.).
Development and progression of the atherosclerotic
lesion.
Evolution, progression and reversal of human atherosclerotic lesions
(B.G. Brown et al.).
Pathobiology of directional
atherectomy specimens from de novo and restenotic coronary lesions
(J. Escaned, P.W. Serruys).
Role of thrombosis and hematoma in atherosclerosis
progression
(H.B. Ravn, S.D. Kristensen, E. Falk).
Natural history of atherosclerosis: the sequence of changes in lesion composition
(H.C. Stary).
Epidemiology: new risk factors.
Alcohol consumption and coronary heart disease: some recent epidemiological data
(P. Ducimetiere).
New risk factors in the Atherosclerosis Risk in Communities Study
(A.R. Folsom, for the Atherosclerosis Risk in Communities
Study (ARIC) Investigators).
von Willebrand factor, endothelial cell markers and arterial thrombosis
(A. Blann).
Homocysteine as a risk
factor for cardiovascular disease
(I.M. Graham, R. Meleady).
Advances in cardiovascular risk prediction: new biochemical and genetic
markers
(J.M. Ordovas).
Molecular genetics of atherosclerosis.
Structure and function of alleles in the 3' end region of human
apoB gene
(B.S. Chen et al.).
A transracial analysis of common genetic variants that relate to coronary artery disease
(Q.
Zhang et al.).
Lessons from molecular defects in secretion, transport and reverse transport of cholesterol
(H. Mabuchi et
al.).
Genetic architecture of the quantitative lipoprotein(a) trait
(G. Utermann, H.G. Kraft).
Lipoprotein oxidation and atherosclerosis.
Endothelial activation in atherogenesis roles of oxidized LDL and lysophosphatidylcholine
(N. Kume, T. Kita).
A role for macrophage
scavenger receptors in atherosclerosis
(K. Inoue et al.).
Lipoprotein oxidation in human atherosclerosis
(R. Stocker et
al.).
Macrophages, LDL oxidation and atherosclerosis
(M. Aviram).
Elevated homocyst(e)ine increases the ability of human aortic
cells to oxidize LDL
(M. Naruszewicz).
Effect of -tocopherol on scavenger receptor activity, mRNA expression and regulation in macrophages
(D. Teupser et al.).
Nutrition and CHD.
Dietary composition and low-density lipoprotein (LDL) modifications
(R. Carmena et al.).
Nutrient composition and the metabolic syndrome
(S.M. Grundy).
The effects of the Mediterranean diet on glucose metabolism
and insulin sensitivity
(M. Mancini).
Clinical efficacy of soy proteins and evaluation of the potential mechanisms of their cholesterol-lowering
effect
(C.R. Sirtori et al.).
The epidemiology of vitamin E and coronary heart disease
(M.J. Stampfer, E.B. Rimm).
Lp(a)
and athero-thrombosis.
Lipoprotein(a) and the endothelium: a feedback loop in atherosclerosis
(D.J. Grainger et al.).
The human very low density lipoprotein receptor mediates the uptake and degradation of lipoprotein(a)
(K. McTigue Argraves et al.).
Assembly and catabolism of lipoprotein(a)
(W. Xingde et al.).
Function and evolution of Lp(a)
(R.M. Lawn).
Comparative effects
of Desogen(R) and Lo/Ovral(TM) contraceptive hormones on lipoprotein(a)
(J.D. Morrisett et al.).
Triglycerides are an independent
risk factor for coronary heart disease a debate.
The epidemiologic case for triglyceride as a risk factor for cardiovascular disease
(M.A. Austin, J.E. Hokanson).
The clinical case for triglyceride-rich lipoproteins
(G.R. Thompson).
The relationship of triglycerides
and LDL cholesterol to coronary heart disease
(O. Faergeman).
Growth factors, cytokines and vasoactive peptides.
Regulation of
apoptosis in vascular smooth muscle cells
(M.R. Bennett).
Potential roles of extracellular nucleotides in atherosclerosis and restenosis
(A.-P. Gadeau).
PDGF and arterial smooth muscle hyperplasia. Possible modulation by thrombin
(G. Fager).
Retinoids and arterial smooth
muscle cells
(P. Neuville, G. Gabbiani).
Epidemiology: geographical variations of cardiovascular incidence and risk factors.
Geographical variation of cardiovascular incidence and risk factors: a comparison of the data of an Asian (Singapore) and a European
(PROCAM) Study
(Q.W. Yong, S. Tavintharan, L.S. Chew).
Association of westernized lifestyle and coronary risk factors in the Japanese
(G. Egusa, M. Yamakido).
Geographic variation and time trends in stroke occurrence
(C. Sarti, J. Tuomilehto).
Secular trends in cardiovascular
risk factor levels: a Framingham perspective
(P.W.F. Wilson, R.B. D'Agostino, W.B. Kannel).
Gene therapy of atherosclerosis and
restenosis.
Novel approach to somatic gene therapy for dyslipidemia
(L. Chan, K. Kobayashi, K. Oka).
Gene therapy of vascular disorders.
Use of gax gene transfer as a molecular strategy to prevent postangioplasty restenosis
(A. Le Roux et al.).
CKIs and regulation
of cell cycle in vascular cells
(F.C. Tanner et al.).
Adventitial gene transfer to rabbit carotid arteries
(M. Laitinen, S.
Yla-Herttuala).
Molecular genetics of monogenic disorders of lipoprotein metabolism.
Redefining familial lipoprotein lipase
deficiency in the era of molecular medicine
(P. Benlian).
Molecular genetics of familial hypercholesterolemia in Italy. Outcomes and
future prospects
(S. Calandra, S. Bertolini).
Familial hypercholesterolemia: molecular genetics and clinical expression
(J.C. Defesche,
M.E. Wittekoek, J.J.P. Kastelein).
Familial HDL deficiency syndromes
(H. Funke).
Expression of gamma-IFN responsive genes in monocytes
is associated with xanthomatosis
(T. Grewal et al.).
FDB: diagnosis, laboratory and clinical findings, possibilities of treatment.
Experience from homozygous and heterozygous patients
(R. Ceska et al.).
Coagulation and fibrinolysis.
Thrombin interaction
with vascular and nonvascular cells
(M.-C. Guillin et al.).
Impaired fibrinolysis and the risk of coronary heart disease
(I.
Juhan-Vague, M.C. Alessi).
Does tissue factor participate in angiogenesis?
(A. Bierhaus et al).
Triglyceride-rich lipoprotein.
Different approaches to the detection and quantification of triglyceride-rich lipoprotein remnants
(J.S. Cohn, J. Davignon).
Mechanism
of the production of small dense LDL (sLDL) in hypertriglyceridemia
(Y. Ikeda et al.).
Regulation of VLDL production in man:
implications for coronary heart disease (CHD)
(C.J. Packard, J. Shepherd).
Effect of triglyceride-rich lipoproteins on cholesterol transport
and atherosclerosis
(J.R. Patsch).
Genetics of elevated apolipoprotein-B and dense LDL in familial combined hyperlipidemia
(S.J.H.
Bredie et al.).
Hormonal replacement therapy of menopause and atherosclerosis.
Estrogen replacement therapy and atherosclerosis
(E. Barrett-Connor).
Effects of estrogen on the endothelium in postmenopausal women: implications for atherosclerosis
(R.O. Cannon
III).
The influence of hormone replacement therapy usage following successful coronary balloon angioplasty
(G. Lloyd et al.).
The effect of hormone replacement therapy and route of administration on selected cardiovascular risk factors in postmenopausal women
(M. Seed et al.).
Hormonal agents used in lowering lipoprotein(a)
(R. Baetta et al.).
HDL reverse cholesterol
transport.
Structural and functional consequences of nonenzymatic glycation of apolipoprotein A-I and its impact on the reverse
cholesterol transport
(C. Calvo).
Caveolin-dependent free cholesterol efflux
(C.J. Fielding, P.E. Fielding, A. Bist).
Is plasma HDL
concentration rate-limiting for reverse cholesterol transport?
(N.E. Miller).
High-density lipoproteins and cellular cholesterol efflux
(M.C. Phillips et al.).
Genetic determinants of HDL and their relationships to atherosclerosis
(A.R. Tall et al.).
Lipoprotein cell interactions.
Cellular catabolism of triglyceride-rich lipoproteins
(J. Heeren, U. Beisiegel).
The effect
of leukaemia inhibitory factor on experimental atherosclerosis
(J.H. Campbell, C.S. Moran, G.R. Campbell).
Lipoprotein association with
cells and matrix: modulation by lipase and proteoglycans
(I.J. Goldberg et al.).
Arterial-wall sphingomyelinase and atherogenesis
(I. Tabas et al.).
Lipid oxidation products as regulators of macrophage function in atherosclerosis
(O. Wiklund et al.).
Health economy and hypolipidemic drugs.
Rationale and effectiveness of lipid therapy
(E. Windler, B.-C. Zyriax, H. Greten).
The economic implications of lipid-lowering therapy: vice or virtue
(T.D. Szucs).
The cost-effectiveness of simvastatin treatment to
lower cholesterol in patients with coronary heart disease
(F. Ørnskov).
Cost-effectiveness of primary prevention of myocardial
infarction using statins in Germany
(K.W. Lauterbach, M. Danner).
Cellular and haemodynamic regulation of endothelial function.
Hemodynamic forces and vascular cell communication
(P.F. Davies, N. DePaola, D. Polacek).
Vascular endothelium, hemodynamic forces
and atherogenesis
(M.A. Gimbrone Jr., J.N. Topper).
Endothelial VCAM-1 gene regulation by steady and oscillatory shear stress
(S.E.
Varner et al.).
Interaction between red blood cells and endothelium
(J.-L. Wautier, M.-P. Wautier).
Suppression of gap junctional
intercellular communication in HUVEC by neutrophil adhesion
(S. Murota, M. Nishida, I. Morita).
Immune and infectious factors in
atherogenesis.
Cytomegalovirus and vasculopathy an overview
(C.A. Bruggeman).
Autoimmunity in atherosclerosis
(G.K. Hansson et al.).
Potential roles of mast cells in atherosclerosis: from fatty streaks to plaque rupture
(P.T. Kovanen).
Autoimmunity
to heat shock proteins in atherosclerosis
(G. Wick, Q. Xu).
New development in animal models for atherosclerosis.
Effect of
multiple gene transfer in mouse models
(S. Seguret-Mace et al.).
Overexpression of human apoC1 in transgenic mice inhibits
binding of VLDL to LRP and the VLDL receptor
(M.C. Jong et al.).
Analysis of chylomicron remnant metabolism by tissue-specific
gene inactivation
(A. Rohlmann et al.).
Transgenic dissection of atherogenic profiles of plasma lipoproteins and arterial wall
metabolism
(S. Ishibashi et al.).
Strategies for altering the mouse genome and their application in the study of atherogenesis
(M.E. Hinsdale et al.).
Genetic epidemiology of CHD and its risk factors.
Genetic susceptibility factors for restenosis
after coronary angioplasty
(P. Amouyel, C. Bauters).
Genetics, lipoproteins disorders and premature coronary artery disease
(J. Genest
Jr, M. Marcil).
Predisposing genes, high-risk environments and coronary artery disease: LPL and MMP-3 as examples
(S.E. Humphries et
al.).
A quantitative genetic analysis of the angiotensin-1 converting enzyme (ACE) gene
(B. Keavney et al.).
Insulin
resistance and lipoprotein metabolism.
Abnormal reverse cholesterol transport in type II diabetes mellitus
(F.D. Brites et
al.).
The insulin-resistant dyslipidemic syndrome of visceral obesity: an atherogenic cluster
(J.-P. Despres).
Insulin resistance,
atherosclerosis and CHD
(S.M. Haffner).
Lipoprotein abnormalities and insulin resistance
(R.W. James).
Is insulin regulation of VLDL
production defective in insulin resistance?
(M.-R. Taskinen et al.).
Platelets.
Proteolytically activated receptors
in the regulation of hemostasis
(W.F. Bahou).
Integrin signalling kinases and their influence on the formation of lipid intermediates
during platelet responses
(K. Missy et al.).
The respective roles of GPIb and GPIIb-IIIa in blood platelet adhesion
(J.J.
Sixma, P.G. de Groot).
Molecular requirements for ligand recognition by 3 integrins
(T.J. Kunicki).
Molecular insights into HDL
and its properties.
Structure-function relationships in apolipoprotein A-I: insights from the A-IMilano mutation
(G. Franceschini et al.).
Tryptophan residues stabilize the N-terminal domain of apolipoprotein A-I and promote its anchoring to lipid surfaces
(W.S. Davidson, K. Arnvig McGuire, A. Jonas).
Interaction of the cholesteryl ester transfer protein with high-density lipoproteins from
human and mouse plasmas
(D. Masson et al.).
Definition of apolipoprotein A-I domains involved in reverse cholestero transport
(Y.L. Marcel, P.G. Frank).
Contribution of apo AII and LCAT oblique peptides to HDL metabolism
(B. Vanloo et al.).
Noninvasive
assessment of atherosclerosis.
Common carotid artery intimal-medial thickness and risk of coronary heart disease
(J.R. Crouse III).
Magnetic resonance imaging and angiography of atherosclerosis
(R.R. Edelman).
Coronary calcification as a marker of arterial disease
(A. Simon et al.).
Vascular endpoints for quantitating atherosclerosis for human gene therapy clinical trials
(J.M. Hoeg et
al.).
The clinical evaluation, development and regulation of new drugs,
agents, substances affecting atherosclerosis cardiovascular
diseases
by lipoprotein related mechanisms
.
What guidelines are necessary to demonstrate efficacy and safety in "special" groups:
women as a paradigm
(J.C. LaRosa).
Index of authors. Keyword index.
Bibliographic & ordering Information
Hardbound, 1228 pages, publication date: MAY-1998
ISBN-13: 978-0-444-82651-0
ISBN-10: 0-444-82651-3
Imprint: EXCERPTA MEDICA
Price: Order form
GBP 184
USD 276
EUR 276
Books and book related electronic products are priced in US dollars (USD), euro (EUR), and Great Britain Pounds (GBP). USD prices apply to the Americas and Asia Pacific. EUR prices apply in Europe and the Middle East. GBP prices apply to the UK and all other countries.
See also information about conditions of sale & ordering procedures, and links to our regional sales offices.
096/960
Last update: 25 Aug 2008
|
|
| |
| | |
|
|
| |
